Imunon (IMNN) Competitors $5.76 +0.04 (+0.70%) Closing price 04:00 PM EasternExtended Trading$5.76 0.00 (-0.09%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMNN vs. PDSB, DTIL, ATNM, INMB, IMA, CLNN, VRCA, JMAC, VTVT, and FGENShould you be buying Imunon stock or one of its competitors? The main competitors of Imunon include PDS Biotechnology (PDSB), Precision BioSciences (DTIL), Actinium Pharmaceuticals (ATNM), INmune Bio (INMB), ImageneBio (IMA), Clene (CLNN), Verrica Pharmaceuticals (VRCA), Maxpro Capital Acquisition (JMAC), vTv Therapeutics (VTVT), and FibroGen (FGEN). These companies are all part of the "pharmaceutical products" industry. Imunon vs. Its Competitors PDS Biotechnology Precision BioSciences Actinium Pharmaceuticals INmune Bio ImageneBio Clene Verrica Pharmaceuticals Maxpro Capital Acquisition vTv Therapeutics FibroGen PDS Biotechnology (NASDAQ:PDSB) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings. Which has preferable earnings & valuation, PDSB or IMNN? Imunon has higher revenue and earnings than PDS Biotechnology. PDS Biotechnology is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPDS BiotechnologyN/AN/A-$37.61M-$0.92-1.30Imunon$500K28.11-$18.62M-$12.95-0.44 Does the media refer more to PDSB or IMNN? In the previous week, PDS Biotechnology and PDS Biotechnology both had 2 articles in the media. PDS Biotechnology's average media sentiment score of 0.88 beat Imunon's score of 0.50 indicating that PDS Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PDS Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Imunon 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, PDSB or IMNN? PDS Biotechnology has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Imunon has a beta of 2.29, meaning that its share price is 129% more volatile than the S&P 500. Do analysts prefer PDSB or IMNN? PDS Biotechnology currently has a consensus price target of $10.00, suggesting a potential upside of 733.33%. Imunon has a consensus price target of $232.50, suggesting a potential upside of 3,936.46%. Given Imunon's higher possible upside, analysts clearly believe Imunon is more favorable than PDS Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PDS Biotechnology 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Imunon 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.75 Do institutionals & insiders believe in PDSB or IMNN? 26.8% of PDS Biotechnology shares are held by institutional investors. Comparatively, 4.5% of Imunon shares are held by institutional investors. 9.2% of PDS Biotechnology shares are held by company insiders. Comparatively, 6.0% of Imunon shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is PDSB or IMNN more profitable? PDS Biotechnology's return on equity of -184.56% beat Imunon's return on equity.Company Net Margins Return on Equity Return on Assets PDS BiotechnologyN/A -184.56% -79.00% Imunon N/A -405.07%-158.41% SummaryPDS Biotechnology beats Imunon on 8 of the 14 factors compared between the two stocks. Get Imunon News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMNN vs. The Competition Export to ExcelMetricImunonMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.05M$3.16B$5.78B$9.92BDividend YieldN/A2.28%6.67%4.52%P/E Ratio-0.4421.1175.6726.67Price / Sales28.11463.83554.40206.13Price / CashN/A45.1137.1158.92Price / Book1.519.8611.446.09Net Income-$18.62M-$53.47M$3.28B$266.14M7 Day Performance-2.87%2.79%0.78%0.22%1 Month Performance-34.25%8.49%7.07%4.08%1 Year Performance-62.72%13.61%59.61%23.89% Imunon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMNNImunon2.1948 of 5 stars$5.76+0.7%$232.50+3,936.5%-63.7%$14.05M$500K-0.4430Short Interest ↓PDSBPDS Biotechnology2.6404 of 5 stars$1.24flat$10.00+706.5%-59.5%$57.83MN/A-1.3520DTILPrecision BioSciences3.9539 of 5 stars$4.90-2.4%$47.00+859.2%-49.2%$57.76M$68.70M-0.56200ATNMActinium Pharmaceuticals1.7677 of 5 stars$1.78+2.3%$4.50+152.8%-6.1%$55.53MN/A-1.2830Short Interest ↑INMBINmune Bio2.201 of 5 stars$2.03-2.9%$18.40+806.4%-68.8%$53.97M$10K-0.8210IMAImageneBio2.9275 of 5 stars$13.40-0.4%$35.50+164.9%-57.8%$53.87M$9.16M-1.7470News CoverageCLNNClene3.7157 of 5 stars$5.32-1.7%$33.00+520.3%-10.7%$53.15M$340K-1.41100News CoverageVRCAVerrica Pharmaceuticals4.2331 of 5 stars$5.59+0.7%$80.00+1,331.1%-77.6%$52.85M$7.57M-0.6840JMACMaxpro Capital AcquisitionN/A$3.93-6.1%N/A+3,608.0%$52.80MN/A0.002,021VTVTvTv Therapeutics1.3141 of 5 stars$15.53-1.7%$35.50+128.7%+23.1%$51.88M$1.02M-4.989Positive NewsHigh Trading VolumeFGENFibroGen4.1479 of 5 stars$11.83+6.3%$43.00+263.5%+13.2%$47.84M$29.62M-31.13570Gap Down Related Companies and Tools Related Companies PDSB Competitors DTIL Competitors ATNM Competitors INMB Competitors IMA Competitors CLNN Competitors VRCA Competitors JMAC Competitors VTVT Competitors FGEN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMNN) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMNN Stock Alerts